Alzheimer's disease drug development pipeline: 2022

临床试验 医学 药物开发 疾病 药品 药物试验 阿尔茨海默病 重症监护医学 药理学 内科学
作者
Jeffrey L. Cummings,Garam Lee,Pouyan Nahed,Mina Esmail Zadeh Nojoo Kambar,Kate Zhong,Jorge Fonseca,Kazem Taghva
出处
期刊:Alzheimer's & Dementia: Translational Research & Clinical Interventions [Wiley]
卷期号:8 (1) 被引量:108
标识
DOI:10.1002/trc2.12295
摘要

Introduction Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs in development for the treatment of AD. Methods We searched the governmental website clinicaltrials.gov where are all clinical trials conducted in the United States must be registered. We used artificial intelligence (AI) and machine learning (ML) approaches to ensure comprehensive detection and characterization of trials and drugs in development. We use the Common Alzheimer's Disease Research Ontology (CADRO) to classify drug targets and mechanisms of action of drugs in the pipeline. Results As of January 25, 2022 (index date for this study) there were 143 agents in 172 clinical trials for AD. The pipeline included 31 agents in 47 trials in Phase 3, 82 agents in 94 trials in Phase 2, and 30 agents in 31 trials in Phase 1. Disease-modifying therapies represent 83.2% of the total number of agents in trials; symptomatic cognitive enhancing treatments represent 9.8% of agents in trials; and drugs for the treatment of neuropsychiatric symptoms comprise 6.9%. There is a diverse array of drug targets represented by agents in trials including nearly all CADRO categories. Thirty-seven percent of the candidate agents in the pipeline are repurposed drugs approved for other indications. A total of 50,575 participants are needed to fulfill recruitment requirements for all currently active clinical trials. Discussion The AD drug development pipeline has agents representing a substantial array of treatment mechanisms and targets. Advances in drug design, outcome measures, use of biomarkers, and trial conduct promise to accelerate the delivery of new and better treatments for patients with AD. Highlights There are 143 drugs in the current Alzheimer's disease (AD) drug development pipeline. Disease-modifying therapies represent 83.2% of the candidate treatments. Current trials require 50,575 participants who will donate 3,878,843 participant-weeks to clinical trials. The biopharmaceutical industry sponsors 50% of all clinical trials including 68% of Phase 3 trials. Sixty-three percent of Phase 3 trials and 46% of Phase 2 trials include non–North American clinical trial site locations indicating the global ecosystem required for AD drug development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
坚强的铅笔完成签到 ,获得积分10
1秒前
1秒前
2秒前
小李之家发布了新的文献求助10
2秒前
txh12323发布了新的文献求助10
5秒前
明亮忆秋发布了新的文献求助10
6秒前
充电宝应助清新的冷松采纳,获得10
6秒前
9秒前
田様应助fan采纳,获得10
9秒前
安静落雁完成签到 ,获得积分10
10秒前
11秒前
11秒前
Rose发布了新的文献求助20
13秒前
13秒前
跳跃毒娘发布了新的文献求助10
14秒前
14秒前
15秒前
15秒前
000发布了新的文献求助10
15秒前
科研通AI2S应助草木采纳,获得10
16秒前
18秒前
aaa发布了新的文献求助10
19秒前
刘欢发布了新的文献求助10
19秒前
明亮忆秋完成签到,获得积分20
19秒前
种桃老总发布了新的文献求助10
20秒前
JiaqiDijon完成签到,获得积分10
20秒前
王贺完成签到,获得积分10
20秒前
freeaway发布了新的文献求助10
21秒前
星辰大海应助lisa采纳,获得10
22秒前
22秒前
24秒前
科研通AI2S应助科研通管家采纳,获得10
24秒前
科研通AI2S应助科研通管家采纳,获得10
24秒前
田様应助科研通管家采纳,获得10
24秒前
24秒前
科研通AI2S应助科研通管家采纳,获得10
24秒前
星辰大海应助科研通管家采纳,获得10
24秒前
领导范儿应助科研通管家采纳,获得10
24秒前
科目三应助科研通管家采纳,获得10
24秒前
科研通AI2S应助科研通管家采纳,获得10
24秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
COSMETIC DERMATOLOGY & SKINCARE PRACTICE 388
Case Research: The Case Writing Process 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3141752
求助须知:如何正确求助?哪些是违规求助? 2792710
关于积分的说明 7803941
捐赠科研通 2448986
什么是DOI,文献DOI怎么找? 1303011
科研通“疑难数据库(出版商)”最低求助积分说明 626717
版权声明 601244